Pacira Pharmaceuticals, Inc. (PCRX) Receives “Hold” Rating from Cowen and Company
“Nerve block data for Exparel is anticipated within the next month, and our consultants.”,” Cowen and Company’s analyst commented.
A number of other equities research analysts have also recently commented on PCRX. HC Wainwright set a $59.00 target price on Pacira Pharmaceuticals and gave the stock a buy rating in a research note on Saturday, May 6th. Royal Bank Of Canada set a $58.00 target price on Pacira Pharmaceuticals and gave the stock a buy rating in a research note on Tuesday, June 27th. BidaskClub upgraded Pacira Pharmaceuticals from a sell rating to a hold rating in a research note on Wednesday, July 5th. Wedbush reiterated an outperform rating and set a $87.00 target price on shares of Pacira Pharmaceuticals in a research note on Wednesday, May 24th. Finally, Mizuho lowered their target price on Pacira Pharmaceuticals from $59.00 to $54.00 and set a buy rating on the stock in a research note on Thursday, March 23rd. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and eight have assigned a buy rating to the stock. The company presently has an average rating of Hold and a consensus target price of $55.25.
Pacira Pharmaceuticals (NASDAQ PCRX) traded down 0.30% during midday trading on Friday, hitting $49.15. 489,799 shares of the company were exchanged. The stock’s market capitalization is $1.97 billion. The firm’s 50-day moving average price is $46.14 and its 200-day moving average price is $43.48. Pacira Pharmaceuticals has a one year low of $29.95 and a one year high of $58.95.
Pacira Pharmaceuticals (NASDAQ:PCRX) last released its earnings results on Thursday, May 4th. The company reported ($0.19) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.23) by $0.04. The company had revenue of $69.30 million for the quarter, compared to analysts’ expectations of $70.30 million. Pacira Pharmaceuticals had a negative return on equity of 7.71% and a negative net margin of 19.26%. The business’s revenue for the quarter was up 5.8% compared to the same quarter last year. During the same period in the previous year, the business posted $0.15 EPS.
In other news, CEO David M. Stack sold 4,311 shares of the company’s stock in a transaction dated Monday, June 5th. The stock was sold at an average price of $43.32, for a total transaction of $186,752.52. Following the sale, the chief executive officer now directly owns 59,559 shares in the company, valued at $2,580,095.88. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, VP Lauren Bullaro Riker sold 601 shares of the company’s stock in a transaction dated Monday, June 5th. The shares were sold at an average price of $43.32, for a total value of $26,035.32. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 50,564 shares of company stock worth $2,506,682. Company insiders own 6.60% of the company’s stock.
Large investors have recently made changes to their positions in the stock. Benjamin F. Edwards & Company Inc. boosted its stake in shares of Pacira Pharmaceuticals by 85.6% in the first quarter. Benjamin F. Edwards & Company Inc. now owns 2,491 shares of the company’s stock valued at $114,000 after buying an additional 1,149 shares in the last quarter. FNY Partners Fund LP bought a new stake in shares of Pacira Pharmaceuticals during the first quarter valued at $136,000. Ameritas Investment Partners Inc. bought a new stake in shares of Pacira Pharmaceuticals during the first quarter valued at $144,000. Amalgamated Bank bought a new stake in shares of Pacira Pharmaceuticals during the first quarter valued at $204,000. Finally, Trexquant Investment LP bought a new stake in shares of Pacira Pharmaceuticals during the first quarter valued at $237,000.
About Pacira Pharmaceuticals
Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.
Receive News & Ratings for Pacira Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.